FIGURE 1.

Combination of molecular targeted agents and VEGFR2 blockade in xenograft mouse models. Mice were transplanted with PC‐9, H3255, H3122, ABC‐11, or ABC‐20 cells. Molecular targeted agents were orally administered 5 times weekly. DC101 was administered intraperitoneally (10 mg/kg/d) twice weekly. A, B, Mice bearing PC‐9 or H3255 tumors were treated with vehicle, erlotinib (30 mg/kg/d), DC101, or erlotinib plus DC101 combination. In H3255‐transplanted mice, the erlotinib dose was reduced to 15 mg/kg/d from day 21, and the treatment was discontinued from day 53. C, D, Mice bearing H3122 and ABC‐11 tumors were treated with vehicle, alectinib (10 mg/kg/d), DC101, or alectinib plus DC101 combination. E, Mice bearing ABC‐20 tumors were treated with vehicle, crizotinib (50 mg/kg/d), DC101, or crizotinib plus DC101 combination. Error bars represent standard errors; *P < .05